Moleculin Stock Performance

MBRX
 Stock
  

USD 1.45  0.05  3.33%   

The company secures a Beta (Market Risk) of 0.9884, which conveys possible diversification benefits within a given portfolio. Let's try to break down what Moleculin's beta means in this case. Moleculin Biotech returns are very sensitive to returns on the market. As the market goes up or down, Moleculin Biotech is expected to follow. Even though it is essential to pay attention to Moleculin Biotech price patterns, it is always good to be careful when utilizing equity historical price patterns. Our philosophy towards estimating any stock's future performance is to check both, its past performance charts as well as the business as a whole, including all available technical indicators. Moleculin Biotech exposes twenty-one different technical indicators, which can help you to evaluate its performance. Moleculin Biotech has an expected return of -0.29%. Please be advised to verify Moleculin Biotech CS coefficient of variation, maximum drawdown, as well as the relationship between the Maximum Drawdown and skewness to decide if Moleculin Biotech performance from the past will be repeated at some point in the near future.
  
Refresh
Moleculin Performance
0 of 100
Over the last 90 days Moleculin Biotech CS has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in July 2022. The current disturbance may also be a sign of long term up-swing for the company investors. ...more

Structure and Payout Changes

Last Split Factor
1:6
Dividend Date
2021-02-01
Last Split Date
2021-02-01

Moleculin Price Channel

Quick Ratio19.59
Fifty Two Week Low1.0200
Target High Price29.00
Fifty Two Week High3.9100
Target Low Price1.57

Moleculin Biotech Relative Risk vs. Return Landscape

If you would invest  182.00  in Moleculin Biotech CS on April 1, 2022 and sell it today you would lose (37.00)  from holding Moleculin Biotech CS or give up 20.33% of portfolio value over 90 days. Moleculin Biotech CS is currently does not generate positive expected returns and assumes 3.9554% risk (volatility on return distribution) over the 90 days horizon. In different words, 34% of stocks are less volatile than Moleculin, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
 Daily Expected Return (%) 
      Risk (%) 
Given the investment horizon of 90 days Moleculin Biotech is expected to under-perform the market. In addition to that, the company is 2.74 times more volatile than its market benchmark. It trades about -0.07 of its total potential returns per unit of risk. The DOW is currently generating roughly -0.13 per unit of volatility.

Moleculin Biotech Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Moleculin Biotech's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Moleculin Biotech CS, and traders can use it to determine the average amount a Moleculin Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = -0.0728

Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small Returns
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
Negative ReturnsMBRX
Estimated Market Risk
 3.96
  actual daily
 
 34 %
of total potential
 
3434
Expected Return
 -0.29
  actual daily
 
 0 %
of total potential
 
00
Risk-Adjusted Return
 -0.07
  actual daily
 
 0 %
of total potential
 
00
Based on monthly moving average Moleculin Biotech is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Moleculin Biotech by adding it to a well-diversified portfolio.

About Moleculin Biotech Performance

To evaluate Moleculin Biotech Stock as a possible investment, you need to clearly understand its upside potential, downside risk, and overall future performance outlook. You may be satisfied when Moleculin Biotech generates a 15% return over the last few months, but what if the market is generating 25% over the same period? In this case, it makes sense to compare Moleculin Stock's performance with different market indexes, such as the Dow or NASDAQ Composite. These indexes can act as benchmarks that will help you to understand Moleculin Biotech stock market performance in a much more refined way. At Macroaxis, we take it even further. The Macroaxis performance score is an integer between 0 and 100 that represents Moleculin's market performance from a risk-adjusted return perspective. Generally speaking, the higher the score, the better is overall performance as compared to other investors. The score is normalized against the average investing universe (the best we can interpret from the data available). Within this methodology, scores of individual equity instruments will always be inferior to the scores of portfolios of equities as portfolios typically diversify a lot of unsystematic risks away. The formula to derive the Macroaxis score bases on multiple unequally-weighted factors. For more information, refer to our portfolio performance evaluation section.
Please also refer to our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Effect of Exchange Rate Changes on Cash-24 K-24.6 K
Return on Average Assets(0.17) (0.19) 
Return on Average Equity(0.19) (0.21) 
Return on Invested Capital 12.21  12.52 
Return on Sales(7.74) (8.35) 
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas. Moleculin Biotech operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 13 people.

Things to note about Moleculin Biotech

Checking the ongoing alerts about Moleculin Biotech for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Moleculin Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.

Moleculin Biotech Alerts

Equity Alerts and Improvement Suggestions

Moleculin Biotech generated a negative expected return over the last 90 days
Moleculin Biotech may become a speculative penny stock
Moleculin Biotech has high historical volatility and very poor performance
Moleculin Biotech has high likelihood to experience some financial distress in the next 2 years
Net Loss for the year was (15.89 M) with profit before overhead, payroll, taxes, and interest of 0.
Moleculin Biotech CS currently holds about 70.9 M in cash with (18.95 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.48, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Moleculin Biotech has a very weak financial position based on the latest SEC disclosures
Latest headline from MacroaxisInsider: Acquisition by Yan Joy of 15000 shares of Moleculin Biotech subject to Rule 16b-3
Additionally, see Stocks Correlation. Note that the Moleculin Biotech information on this page should be used as a complementary analysis to other Moleculin Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Complementary Tools for Moleculin Stock analysis

When running Moleculin Biotech price analysis, check to measure Moleculin Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moleculin Biotech is operating at the current time. Most of Moleculin Biotech's value examination focuses on studying past and present price action to predict the probability of Moleculin Biotech's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moleculin Biotech's price. Additionally, you may evaluate how the addition of Moleculin Biotech to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Go
Shere Portfolio
Track or share privately all of your investments from the convenience of any device
Go
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Go
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Go
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Is Moleculin Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moleculin Biotech. If investors know Moleculin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moleculin Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
42.9 M
Return On Assets
-0.17
Return On Equity
-0.23
The market value of Moleculin Biotech is measured differently than its book value, which is the value of Moleculin that is recorded on the company's balance sheet. Investors also form their own opinion of Moleculin Biotech's value that differs from its market value or its book value, called intrinsic value, which is Moleculin Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moleculin Biotech's market value can be influenced by many factors that don't directly affect Moleculin Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moleculin Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine Moleculin Biotech value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moleculin Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.